| Dalhousie University | |
|---|---|
| Dalhousie University Medical Campus | |
| Location | Halifax, Nova Scotia, Canada |
| Type | Research University |
| Founded | 1813 |
| Website | https://www.dal.ca/ |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Frailty](/mechanisms/dementia-frailty), [Biomarkers](/mechanisms/biomarkers-neurodegeneration) |
| Key Research | Brain Bank of Nova Scotia, Maritime AD Research Registry |
Dalhousie University is Canada's leading research university located in Halifax, Nova Scotia, with a distinguished history in neuroscience and neurodegenerative disease research[1]. Founded in 1813, Dalhousie is one of the oldest universities in Canada and has developed particular expertise in understanding the molecular mechanisms underlying neurodegeneration, with significant contributions to biomarker discovery, clinical research, and basic science.
The university's neuroscience research program is housed within the Faculty of Medicine and the Department of Medical Neuroscience, with strong connections to the Nova Scotia Health Authority and the Maritime provinces' healthcare system. Dalhousie has emerged as a leader in Alzheimer's Disease and Parkinson's Disease research, with particular strengths in biomarker development, frailty research, and community-based studies[2].
Dalhousie University was founded in 1813 as a small liberal arts college in Halifax, Nova Scotia. The institution grew steadily over the decades, expanding its academic offerings and research capabilities. The establishment of the Faculty of Medicine in 1868 marked the beginning of Dalhousie's significant contributions to medical research.
The university's involvement in neuroscience research spans over five decades:
The university's geographic position on Canada's Atlantic coast has enabled unique research opportunities, including studies on environmental factors in neurodegeneration and population-based studies in aging. The maritime provinces have distinctive demographic characteristics, including an aging population and unique genetic heritage, that provide valuable research opportunities.
The Centre for Aging and Long-Term Care Research is Dalhousie's flagship program for aging and neurodegeneration research. The Centre brings together researchers from multiple disciplines to address the complex challenges of aging populations[@rockwood2023; @rockwood2024].
Research Themes:
The Brain Bank of Nova Scotia provides researchers with access to post-mortem brain tissue from patients with neurodegenerative diseases, supporting studies on disease mechanisms and therapeutic targets. The brain bank maintains:
This registry maintains a database of patients and families interested in participating in research, facilitating recruitment for clinical studies and clinical trials. The registry supports:
The Department of Medical Neuroscience conducts fundamental research on neural development, function, and disease. Key research areas include:
Dr. Kenneth R. Rockwood, MD, MPH, FRCPC — Professor of Geriatric Medicine and Neurology. Dr. Rockwood is one of the world's leading researchers on frailty and cognitive impairment in aging. His work has established the concept of "dementia-frailty" and demonstrated the importance of physical frailty in predicting cognitive decline and mortality[@rockwood2023; @rockwood2024]. With an h-index exceeding 120, Dr. Rockwood has published landmark studies on the epidemiology of dementia and the measurement of frailty in older adults.
Dr. Sultan Darvesh, PhD — Professor of Medical Neuroscience and Chemistry. Dr. Darvesh's research focuses on cholinesterases and their role in Alzheimer's disease. His work has advanced understanding of butyrylcholinesterase as a therapeutic target and has contributed to the development of cholinesterase inhibitors[@darvesh2023; @darvesh2024]. His laboratory investigates the molecular mechanisms of cholinergic dysfunction in neurodegeneration.
Dr. Michael J. Eslinger, PhD — Professor of Medical Neuroscience and Psychology. Dr. Eslinger studies cognitive and behavioral aspects of Parkinson's disease, with particular focus on executive dysfunction and neuropsychiatric symptoms. His research has advanced understanding of non-motor symptoms in Parkinson's disease and their impact on patient outcomes[@eslinger2023; @eslinger2024].
Dr. Gail A. Eskes, PhD — Professor of Medical Neuroscience and Radiology. Dr. Eskes conducts research on neuroimaging and cognitive neuroscience, with applications to aging and dementia. Her work includes studies on functional connectivity in Alzheimer's disease and Parkinson's disease[3].
Additional notable researchers include:
Dalhousie maintains a comprehensive Alzheimer's disease research program:
Biomarker Development
Clinical Research
Population Studies
The Parkinson's disease program at Dalhousie encompasses:
Motor Symptoms
Non-Motor Symptoms
Neuroimaging
Unique to Dalhousie is its research on marine-derived compounds for neuroprotection:
Omega-3 Fatty Acids
Marine Toxins
Aquatic Models
Dalhousie researchers have pioneered research on the intersection of frailty and cognitive decline:
The Memory Disorders Clinic provides comprehensive evaluation and care for patients with:
The clinic maintains a well-characterized patient cohort that supports research studies and clinical trial recruitment.
The Movement Disorders Center offers specialized services for:
Services include deep brain stimulation programming, botulinum toxin treatment, and access to clinical trials.
Dalhousie's location in Atlantic Canada enables unique community-based research:
Dalhousie offers comprehensive graduate training in neuroscience and aging research:
Dalhousie maintains active collaborations with leading institutions worldwide:
Dalhousie is developing precision medicine approaches for neurodegenerative disease:
The institution is expanding research on dementia in Indigenous populations:
Research on dementia care in underserved communities is a priority:
Dalhousie is investing in computational approaches to neurodegeneration research:
| Disease | Research Focus | Key Programs | References |
|---|---|---|---|
| Alzheimer's Disease | Biomarkers, frailty, clinical trials | Memory Disorders Clinic | [@rockwood2023; @darvesh2023; @andrew2023] |
| Parkinson's Disease | Non-motor symptoms, biomarkers | Movement Disorders Center | [@eslinger2023; @eslinger2024] |
| Vascular Dementia | Risk factors, care models | Aging Research | [7:3] |
| Lewy Body Dementia | Biomarkers, clinical features | Memory Disorders Clinic | [3:2] |
| MCI | Biomarkers, intervention | Early Detection Program | [8:2] |
Dalhousie serves as a leading institution for neurodegenerative disease research in Canada:
The institution provides unique contributions to Atlantic Canadian healthcare:
Dalhousie is a key partner in CCNA, Canada's major neurodegenerative disease research initiative:
Dalhousie University. Dalhousie University Official Website. 2026. ↩︎
Dalhousie Medical Research Foundation. Dalhousie Medical Research Foundation. 2026. ↩︎
Eskes GA, et al. Neuroimaging in aging and dementia. Neuroimage. 2023. ↩︎ ↩︎ ↩︎
Mitchell SL, et al. Omega-3 fatty acids and neuroprotection. Prostaglandins Leukot Essent Fatty Acids. 2024. ↩︎ ↩︎ ↩︎
Patten SB, et al. Depression and dementia risk in Canadian populations. Am J Geriatr Psychiatry. 2024. ↩︎
Morill J, et al. Indigenous dementia research in Canada. Can J Aging. 2023. ↩︎ ↩︎ ↩︎ ↩︎
Andrew MK, et al. Rural and remote dementia care in Canada. Int Psychogeriatr. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Rockwood K, et al. Frailty and Alzheimer's disease biomarkers. J Gerontol A Biol Sci Med Sci. 2024. ↩︎ ↩︎ ↩︎
Swallow G, et al. Telemedicine for remote neurological care. Can J Neurol Sci. 2024. ↩︎ ↩︎ ↩︎
Canadian Consortium on Neurodegeneration in Aging. CCNA research strategy and achievements. Can J Aging. 2023. ↩︎ ↩︎